Successful treatment of a child with late onset T-cell post-transplant lymphoproliferative disorder/lymphoma
Article first published online: 22 FEB 2007
Copyright © 2007 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 50, Issue 3, pages 667–670, March 2008
How to Cite
Williams, K. M., Higman, M. A., Chen, A. R., Schwartz, C. L., Wharam, M., Colombani, P. and Arceci, R. J. (2008), Successful treatment of a child with late onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr. Blood Cancer, 50: 667–670. doi: 10.1002/pbc.21171
- Issue published online: 9 JAN 2008
- Article first published online: 22 FEB 2007
- Manuscript Accepted: 27 DEC 2006
- Manuscript Received: 19 SEP 2006
- post-transplant lymphoproliferative disorder;
- T-cell lymphoma
We report a novel regimen for refractory post-transplant T-cell lymphoma (PTL). Our patient presented with non-Epstein–Barr virus (EBV) related, T-cell post-transplant lymphoproliferative disease (PTLD) 3.5 years after liver transplantation. Initially diagnosed as polyclonal PTLD, the disease progressed to a monoclonal, T-cell PTL that was refractory to several chemotherapy regimens but responded to a regimen consisting of fludarabine, cyclophosphamide, cytarabine, and alemtuzumab. Consolidation therapy included high-dose chemotherapy, autologous hematopoietic stem cell rescue, and radiation therapy. She remains in remission 2.5 years later. T-cell PTL is a rare disease with a poor prognosis; this regimen provides a novel, potentially curative approach for its treatment. Pediatr Blood Cancer 2008;50:667–670. © 2007 Wiley-Liss, Inc.